2025港股最大Biotech IPO！英矽智能(03696)开启招股：坐拥全球进展最快AI药物

Core Viewpoint - The company Insilico Medicine is set to launch its IPO from December 18 to December 23, aiming to raise significant capital and become a leading player in the AI-driven biotech sector in Hong Kong [1][2]. Group 1: IPO Details - Insilico Medicine plans to issue 94,690,500 H-shares, with 10% allocated for public offering in Hong Kong and 90% for international investors [1]. - The expected share price is HKD 24.05, with a minimum investment of HKD 12,146.27 for 500 shares [1]. - The IPO is projected to be the largest biotech IPO in the Hong Kong market for 2025 [1]. Group 2: Key Investors - The company has secured cornerstone investors including Eli Lilly, Tencent, Temasek, Schroders, UBS, Oak Tree Capital, E Fund, and Taikang Life, with a total subscription of USD 115 million from 15 top-tier investment institutions [1][2]. - Eli Lilly and Tencent represent leading forces in the biopharmaceutical and technology sectors, marking Eli Lilly's first involvement as a cornerstone investor [2]. Group 3: Technology and Pipeline - Insilico Medicine has developed over 20 clinical or IND-stage assets through its proprietary AI platform, Pharma.AI, with three assets licensed to international pharmaceutical and healthcare companies, totaling a contract value of USD 2 billion [2]. - The company’s core asset, Rentosertib (ISM001-055), is expected to be the first AI-discovered drug to enter Phase III clinical trials [3]. - The average development time for a new molecule is less than 18 months, significantly shorter than the traditional average of 4.5 years [3]. Group 4: Commercialization and Collaborations - Insilico Medicine collaborates with 13 of the top 20 pharmaceutical companies globally, enhancing its software platform's reach [3]. - The company has established pipeline licensing collaborations with global pharmaceutical firms such as Exelixis and Menarini, potentially generating USD 2 billion in revenue [3]. - Partnerships with major pharmaceutical companies like Sanofi, Eli Lilly, and Fosun Pharma are in place for drug development [3].